SCVC

Zero Point Motion develops advanced inertial sensors that enable precise positioning and navigation through innovative semiconductor technology. By leveraging cavity optomechanics within a hybrid micro-electro-mechanical system and photonic integrated circuit chip, the company provides ultra-low noise readouts of acceleration and rotation. This technology combines the exceptional noise characteristics of light with the high-volume production capabilities of existing sensors used in various applications, including automotive systems, smartphones, and robotic devices. As a result, Zero Point Motion's solutions enhance the accuracy and reliability of motion tracking in numerous industries.

Theo AI is a company focused on developing an advanced legal prediction engine that aims to provide accurate forecasts of legal dispute outcomes. By utilizing predictive analytics, the engine estimates the odds of success for various cases and determines potential recovery ranges, enabling legal professionals to make better-informed decisions based on data-driven insights. The technology also incorporates learnings from relevant settled cases, enhancing its predictive capabilities. Through these innovations, Theo AI seeks to support the legal community by improving the decision-making process in legal disputes.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly peripheral arterial disease. The company's innovative platform targets altered isoforms of pathogenic messenger ribonucleic acid and vascular endothelial growth factor A, which are implicated in various ischemic conditions. By addressing these specific isoforms, IsomAb aims to enhance blood flow and prevent collateral formation in affected patients. This approach provides new therapeutic options for diseases that currently have limited treatment alternatives, potentially improving outcomes for individuals suffering from these conditions.

Delta G is a gravity sensing hardware and technology development company that specializes in creating advanced underground imaging systems utilizing quantum technology. A spinout from the University of Birmingham, Delta G has developed a gravity gradiometer designed to scan beneath the Earth's surface. This innovative product facilitates utility mapping, supports smart city initiatives, enhances smart mining operations, and aids in building information modeling, enabling various industries to measure gravity gradients effectively and improve the understanding of subsurface conditions.

Scarlet Therapeutics is focused on creating innovative red blood cell-based therapeutics through its proprietary platform for generating therapeutic red blood cells (tRBCs). These tRBCs are designed to carry additional proteins that deliver therapeutic benefits, allowing for broad application across various medical conditions. The company aims to address a range of diseases, including hyperammonemia, hyperoxaluria, metabolic disorders, cancer, and autoimmune diseases. By utilizing cell lines for therapeutic generation rather than relying on donated stem cells, Scarlet Therapeutics seeks to enhance the efficacy of treatments in the healthcare sector, potentially transforming the approach to disease management.

Carbometrics is a specialist chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Founded by the team behind the successful development of a glucose-binding molecule platform, the company leverages over 20 years of research from Professor Anthony Davis’ group at the University of Bristol. Carbometrics aims to create a robust and accurate glucose sensing platform that will lead to an innovative Continuous Glucose Monitoring (CGM) solution, enabling individuals with diabetes to monitor their glucose levels more effectively. Following the sale of their previous venture, Ziylo, to Novo Nordisk, the founders are committed to developing advanced technologies to improve the management of diabetes and enhance patients' quality of life.

VyperCore is a technology company that specializes in the development of modified RISC-V processors aimed at enhancing the performance and security of compute-intensive workloads. By focusing on memory safety, VyperCore's innovative processor technology addresses vulnerabilities commonly associated with traditional computing systems. The company also provides memory allocation management solutions that facilitate the deployment of accelerator cards in data centers, optimizing application software for a diverse range of general-purpose programming languages. Through these advancements, VyperCore seeks to transform the landscape of modern software applications by improving both their efficiency and security.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the ability of these devices to receive weak signals while transmitting, thereby increasing their market reach and accessibility.

Kelpi is a sustainable biotechnology start-up focused on bio-refining seaweed to create innovative bioplastic packaging solutions. The company develops a thin bio-plastic coating designed to replace traditional fossil fuel-based plastics used in packaging for various products, including food, beverages, cosmetics, and personal care items. By utilizing renewable feedstocks, particularly compostable seaweed, Kelpi produces marine-safe coatings for paper and cardboard packaging that have been certified recyclable. This approach allows businesses to eliminate the reliance on single-use plastics, contributing to a more sustainable and environmentally friendly packaging industry.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly peripheral arterial disease. The company's innovative platform targets altered isoforms of pathogenic messenger ribonucleic acid and vascular endothelial growth factor A, which are implicated in various ischemic conditions. By addressing these specific isoforms, IsomAb aims to enhance blood flow and prevent collateral formation in affected patients. This approach provides new therapeutic options for diseases that currently have limited treatment alternatives, potentially improving outcomes for individuals suffering from these conditions.

Open Bionics Ltd. is a company based in Bristol, United Kingdom, founded in 2014, that specializes in the development and manufacturing of robotic bionic hands for amputees, researchers, and hobbyists. The company is known for creating the Hero Arm, a lightweight, multi-grip bionic arm specifically designed for individuals with upper limb differences. This innovative product features a ventilated, adjustable socket and removable aesthetic covers, allowing users to customize the appearance of their bionic arm with popular designs, including those from Disney and iconic characters. Open Bionics aims to make advanced bionic technology more accessible and affordable, enhancing the mobility and quality of life for amputees through personalized assistive devices. The company also offers 3D printed bionic hand kits and components available for purchase online.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Imophoron is a biotechnology company focused on developing a next-generation rapid-response vaccine platform known as ADDomer. This innovative platform is designed to address infectious diseases and potential outbreaks by utilizing a self-assembling thermotolerant protein. This technology allows for the rapid insertion of a large number of peptide and protein epitopes into a single particle, making it well-suited for the creation of next-generation vaccines. By enabling more efficient vaccine development, Imophoron aims to enhance accessibility for patients and healthcare providers in the fight against major diseases.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the ability of these devices to receive weak signals while transmitting, thereby increasing their market reach and accessibility.

Carbometrics is a specialist chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Founded by the team behind the successful development of a glucose-binding molecule platform, the company leverages over 20 years of research from Professor Anthony Davis’ group at the University of Bristol. Carbometrics aims to create a robust and accurate glucose sensing platform that will lead to an innovative Continuous Glucose Monitoring (CGM) solution, enabling individuals with diabetes to monitor their glucose levels more effectively. Following the sale of their previous venture, Ziylo, to Novo Nordisk, the founders are committed to developing advanced technologies to improve the management of diabetes and enhance patients' quality of life.

Cytoseek Limited is a biotechnology company based in Bristol, United Kingdom, that specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Founded in 2017 as a spinout from the University of Bristol, Cytoseek focuses on cell membrane augmentation technology, which enhances the functionality of cell therapies by enabling tissue-specific targeting and improving cell survivability. The company is currently conducting proof of principle studies to validate the efficacy of its technologies and is actively seeking partnerships with other cell therapy organizations to advance its products towards clinical application, with the overarching goal of improving human health.